MedTrace Logo

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00089856 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 626

Last updated 2008-11-05

No results posted yet for this study

Summary

The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.

Conditions

Interventions

BIOLOGICAL

Immunotherapy with allogeneic prostate vaccine

Immunotherapy with allogeneic prostate vaccine

DRUG

Chemotherapy (Taxotere and prednisone)

Chemotherapy (Taxotere and prednisone)

Sponsors & Collaborators

  • Cell Genesys

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States
  • Belgium
  • Canada
  • France
  • Germany
  • Netherlands
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00089856 on ClinicalTrials.gov